Novel Antivirals for Refractory or Resistant CMV Infection

Who should attend

This initiative is intended for transplant surgeons, cardiothoracic surgeons/clinicians, infectious disease clinicians, critical care clinicians, hospitalists, nurses, pharmacists, and other healthcare providers involved in the care of SOT recipients.

Program Overview

Conventional pharmacotherapies prescribed for solid organ transplant (SOT) recipients who develop refractory or resistant cytomegalovirus (CMV) infections have unfavorable safety profiles that significantly cap their utility. As a result, an inhibitor of human CMV enzyme pUL97 and other novel management strategies are progressively emerging to bridge this long-standing therapeutic gap. Accompanying the growth of the therapeutic armamentarium are a number of mounting, complex practice questions that may complicate the use of new therapies and preclude their potential to address unmet needs. Despite the rising prevalence of refractory or resistant CMV infections, their precise definitions still can vary depending on the consulted medical authority; additionally, clinical practice guidelines have not undergone extensive revision to account for the growth in antiviral Medic*tion options. Other questions regarding the optimal duration of use for antivirals, the benefits and risks of combination regimens, and how to resolve infections when second-line options exhibit inadequate efficacy, also are unanswered. These accumulating knowledge and competence gaps collectively illustrate the need for targeted, continuing education directed toward SOT surgeons, cardiothoracic clinicians, infectious disease clinicians, and others involved in managing difficult-to-treat CMV infections. By cultivating deeper familiarity with novel treatment options, these healthcare providers can better personalize care, reduce healthcare costs, and optimize overall, long-term outcomes for SOT recipients.

Agenda

• Examining Unmet Treatment Needs of SOT Recipients with CMV Infections
• Resolving Refractory, Resistant CMV Infections – A Review of the Latest Clinical Trial, Real-World Data
• Combatting a Menace, Victoriously: Improving the Standard of Care for SOT Recipients with Refractory or Resistant CMV Infection
• Conclusion & Q&A

Learning Objectives

• Define refractory or resistant CMV infection in SOT recipients
• Describe risk factors for resistant or refractory CMV infection among patients who have undergone solid organ transplantation
• Compare the efficacy, safety, and mechanisms of action of new antiviral therapy with conventional treatment classes, off-label treatments, and T-cell–based intervention in refractory or resistant CMV in post-SOT patients
• Identify the most appropriate antiviral strategy to prescribe in SOT recipients with a refractory or resistant CMV infection
• Implement care that mitigates the frequency and severity of adverse events tied to antiviral medications indicated in patients with refractory or resistant CMV infection

Commercial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc
This program is in partnership with AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Event Venue & Nearby Stays

Hynes Convention Center, 900 Boylston Street, Boston, United States